NCT06691607

Brief Summary

This single-center prospective non-randomized observational research included 120 critically ill persons, at Sohag University hospital's critical care unit. NGAL serum level was assessed at admission to the intensive care unit (NGAL1) and 24 hours after first sample (NGAL2). Cases were categorized into two groups depending on their progression or not to AKI, group A or group B respectively during their intensive care unit stay. Serum NGAL1 and NGAL2 concentrations were compared in relation to development of AKI (group A) or not (group B), need for RRT or not and in relation to mortality.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2020

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 1, 2020

Completed
1.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2022

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2022

Completed
2.4 years until next milestone

First Submitted

Initial submission to the registry

November 11, 2024

Completed
4 days until next milestone

First Posted

Study publicly available on registry

November 15, 2024

Completed
Last Updated

November 15, 2024

Status Verified

November 1, 2024

Enrollment Period

1.9 years

First QC Date

November 11, 2024

Last Update Submit

November 14, 2024

Conditions

Keywords

Critically ill, neutrophil gelatinase-associated lipocalin, acute kidney injury.

Outcome Measures

Primary Outcomes (1)

  • the capability of serum NGAL levels to identify renal damage early in all patients requiring critical care

    the capability of serum NGAL levels to identify renal damage early in all patients requiring critical care

    through study completion, an average of 1 year

Secondary Outcomes (1)

  • detection of patient outcome either; the need to RRT or patient mortality.

    through study completion, an average of 1 year

Study Arms (2)

Group A

Group A progressed to AKI

Other: Serum NGAL level

Group B

Group B did not progress to AKI

Other: Serum NGAL level

Interventions

serum NGAL level

Group AGroup B

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

All included patients were subjected to the following: History taking, demographic data, full medical history before ICU admission. Complete clinical examination immediately on admission. NGAL was measured by (ELISA) at admission and after 24 hours. Serum level of creatinine was measured immediately on admission and every 24 hours. Routine Laboratory investigations, abdominal ultrasound comment on kidney echogenicity was performed. Utilizing the RIFLE-SCr method, participants were split into two groups: group A that advanced acute kidney injury or failure during their intensive care unit stay, and group B that didn't. Patients with AKI should consider dialysis if they have been indicated.

You may qualify if:

  • \- All severely sick ICU patients older than 18 years old were included in the study

You may not qualify if:

  • Patients with known chronic renal disease, those receiving hemodialysis, those with transplanted kidney, those with known kidney cancer, and patients who were just released from the ICU

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sohag University

Sohag, Sohag Governorate, Egypt

Location

MeSH Terms

Conditions

Critical IllnessAcute Kidney Injury

Condition Hierarchy (Ancestors)

Disease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsRenal InsufficiencyKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital Diseases

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Target Duration
7 Days
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant professor of Anesthesia

Study Record Dates

First Submitted

November 11, 2024

First Posted

November 15, 2024

Study Start

April 1, 2020

Primary Completion

March 1, 2022

Study Completion

June 1, 2022

Last Updated

November 15, 2024

Record last verified: 2024-11

Data Sharing

IPD Sharing
Will not share

no plan to participate indevidual data

Locations